Drug Trial Radar · NCT04555486
Study to Evaluate Safety, Tolerability, PK and PD of DCR-PHXC in PH Type 3 Patients
Last checked: Nov 20, 2026Latest source record: Sep 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Sep 14, 2020
Primary completion
Sep 7, 2021
Study completion Sep 7, 2021
Sponsor
- Lead sponsor
- Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyIndustry
- Sponsor type
- Industry
- First posted
- Sep 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.
Conditions
- Primary Hyperoxaluria Type 3
Interventions
DCR-PHXCDrug
Intervention, drug, DCR-PHXC
Sterile Normal Saline (0.9% NaCl)Drug
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety profile of a single dose of DCR-PHXC in PH3 PatientsTime frame: Screening through Day 85
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
Clinical Trial Site
Boston, Massachusetts
Clinical Trial Site
Rochester, Minnesota
Clinical Trial Site
New York, New York
Clinical Trial Site
Bonn, Germany
Clinical Trial Site
Amsterdam, Netherlands
Clinical Trial Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.